Astrana Health, Inc. (ASTH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with record-high adjusted EPS and optimistic guidance for 2026 and 2027. The integration of Prospect Health and strategic partnerships are progressing well, and AI tools are enhancing operational efficiency. Despite some concerns about Medicaid disenrollments and management's lack of specific quantifications, the overall sentiment is positive. The expanded partnerships and AI deployment are likely to boost short-term stock price, leading to a positive outlook.
Key Financial Performance
Total Revenue (Q4 2025) $950.5 million, increasing 43% year-over-year. The increase was driven by the full quarter contribution from Prospect and continued organic growth in the Care Partners segment.
Adjusted EBITDA (Q4 2025) $52.5 million, up 50% year-over-year. This reflects disciplined execution and well-controlled medical cost performance.
Total Revenue (Full Year 2025) $3.2 billion, representing a 56% year-over-year growth. Growth was driven by the Prospect acquisition and organic growth in core and expansion markets.
Adjusted EBITDA (Full Year 2025) $205.4 million, up 21% year-over-year. This reflects the scalability of the technology-enabled care model and disciplined cost management.
Free Cash Flow (Full Year 2025) $104.5 million, with over 50% conversion rate relative to adjusted EBITDA. This exceeded expectations due to strong underlying cash generation.
California Revenue (2025) Grew 50% year-over-year, reflecting continued strength in foundational markets.
Revenue Outside California (2025) Grew 90% year-over-year, reflecting geographic diversification and scaling of newer markets.
G&A as a Percentage of Revenue (2025) 6.8%, down 75 basis points year-over-year and 110 basis points on an adjusted basis. This reflects operating leverage and efficiency gains.
Net Income Attributable to Astrana (Q4 2025) $6 million, compared to negative $0.15 in the prior year period. This improvement reflects disciplined execution and integration of acquisitions.
Adjusted EPS (Q4 2025) $0.54, reflecting strong financial performance and operational efficiency.
Adjusted EPS (Full Year 2025) $2.20, a record for the company, driven by revenue growth and cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Astrana Care Enablement Technology Platform: The platform drives operating leverage, accelerates time to profitability in new markets, and embeds real-time data and risk infrastructure. It also automates workflows and supports AI-driven automation, improving efficiency and reducing administrative burden.
Geographic Expansion: Revenue outside California grew 90% year-over-year, with 19% of total revenue now from outside California. Expansion into Texas with a fully delegated Medicare Advantage partnership was launched in January 2026.
Revenue Growth: Total revenue for 2025 was $3.2 billion, a 56% year-over-year increase. Fourth-quarter revenue was $950.5 million, up 43% year-over-year.
Cost Management: Medical cost trends were well controlled, with legacy Astrana performing slightly ahead of a 4.5% cost trend projection.
Efficiency Gains: G&A as a percentage of revenue decreased to 6.8% in 2025, down 75 basis points year-over-year, reflecting operating leverage and AI-driven automation.
Risk Progression: Approximately 80% of revenue and 36% of membership are expected to be in full risk arrangements by Q1 2026. Full-risk contracts initially planned for mid-2025 were delayed to early 2026.
Integration of Prospect Health: Integration is on track, with 97% retention of primary care physicians and expected synergies of $12-$15 million annually.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory recalibration: The company faced challenges due to regulatory recalibration, which could impact operational and financial outcomes.
Industry cost pressure: Astrana Health experienced industry-wide cost pressures, which could affect profitability and operational efficiency.
Broader market volatility: Market volatility posed risks to the company's financial stability and strategic execution.
Material weakness in internal controls: A material weakness in internal controls over financial reporting related to acquisition and purchase accounting processes was identified, which could impact financial accuracy and investor confidence.
Elevated medical cost trends: The company noted elevated medical cost trends in the industry, which could affect financial performance and risk management.
Delayed full-risk contracts: Several full-risk contracts expected to commence in mid-2025 were delayed to early 2026, potentially impacting revenue and operational planning.
Medicaid and exchange enrollment declines: Expected declines in Medicaid and exchange enrollment could adversely affect revenue and membership growth.
Adverse selection in Medicaid and exchange disenrollment: Adverse selection associated with Medicaid and exchange disenrollment could lead to higher medical costs and financial strain.
New market entry costs: Incremental costs associated with entering new markets could impact profitability and operational efficiency.
Integration of Prospect Health: The integration of Prospect Health posed challenges, including standardization of financial reporting and alignment of clinical workflows, which could affect operational stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For 2026, revenue is expected to be in the range of $3.8 billion to $4.1 billion, reflecting continued growth across core and expansion markets.
Adjusted EBITDA: Expected to be between $250 million and $280 million for 2026, driven by ramping full-risk contracts, realization of synergies, and sustained cost discipline.
Free Cash Flow: Projected to range between $105 million and $132.5 million for 2026, supported by new full-risk contracts, normalized working capital, and reduced integration-related investments.
First Quarter 2026 Guidance: Revenue is expected to be between $900 million and $1 billion, with adjusted EBITDA between $60 million and $70 million.
Full-Risk Revenue and Membership: Approximately 80% of revenue and over 36% of membership are expected to be in full-risk arrangements by the end of Q1 2026.
Medicare Advantage Rates: 2027 Medicare Advantage advance rate notice suggests a favorable impact for Astrana compared to the industry, due to its care model and conservative risk adjustment approach.
Operating Leverage and Margins: Continued EBITDA margin expansion is expected as revenue scales and AI-driven automation is embedded across the enterprise.
Prospect Integration Synergies: Expected to achieve the high end of $12 million to $15 million in annualized synergies over the coming quarters.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the fourth quarter, Astrana repurchased approximately 634,000 shares at an average price of $22.23, reflecting a disciplined capital allocation framework and confidence in the long-term value of the business. Additionally, the Board increased the maximum aggregate amount of shares that may be purchased under the company's existing stock repurchase program from $50 million to $100 million. The company may continue to make repurchases under the program following the filing of the 10-K.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the expectations of cost trends for 2026, and how are they expected to vary across different patient segments?
A:The cost trends for 2026 are conservatively embedded at just over a 5% trend, slightly higher than the mid-4% range in 2025. This increase is due to potential Medicaid and HIC disenrollments and adverse selection. Medicare Advantage is expected to have a slightly lower trend, while Medicaid, commercial, and HICS are expected to have slightly higher trends.
Q:Can you provide more details on the 2026 EBITDA guide range and the factors contributing to it?
A:The 2026 EBITDA guide range is $250 million to $280 million, consistent with past ranges. The bridge includes a starting point of $205 million, with contributions from Prospect synergies (high single digits of $12-$15 million), full-risk conversion and contract rates (mid-$20 million range), and expansion market improvements ($5-$10 million). Headwinds include Medicaid disenrollments (10%-15%) and rate acuity mismatch (1%-1.5%), totaling a negative $20 million impact. The midpoint of $265 million reflects the operating plan, while the low end assumes all variables are negative.
Q:What is the impact of the 2027 MA advanced notice on Astrana, and how does it affect the $350 million EBITDA target for 2027?
A:Astrana is less impacted by the 2027 MA advanced notice compared to the industry due to its risk adjustment factor of just over 1.0. The organization expects a positive 2.5%-3% rate update, which should allow for margin stability or slight dilution in 2027. The $350 million EBITDA target remains within the range of outcomes, though external changes since the guidance was issued may influence the final results.
Q:What is Astrana's view on the final rate notice for Medicare Advantage, and what growth rate does it expect?
A:Astrana believes the effective growth rate for Medicare Advantage should be in the high single-digit range and has advocated for this with CMS. While it is difficult to predict the final notice, Astrana supports changes to the risk model to ensure fairness and reduce risk coding as a competitive advantage.
Q:What is the revenue and earnings composition of Prospect, and how is the integration progressing?
A:Approximately 10%-15% of Prospect's revenue is fee-for-service, with the majority mapped to the Care Partners segment. Integration is progressing well, with strong provider engagement and retention (97% gross retention among PCPs). The hospital operates in a managed care setting, optimizing quality and value for members.
Q:What are the AI tools contributing to Astrana's operations, and what are the future opportunities?
A:Astrana's AI tools include automated prior authorization approvals, claims processing, fraud detection, and provider-facing tools for real-time data and insights. These tools improve G&A efficiency and scalability, contributing to over 100 basis points of adjusted G&A improvement. Future opportunities include further G&A reductions and enhanced care model execution.
Q:What is the status of the care enablement business, and what are the expectations for its gross margins?
A:The care enablement business has a strong pipeline, with a new client onboarded smoothly. EBITDA margins are expected to remain in the 20%-25% range, consistent with recent quarters.
Q:What are the expectations for Medicaid and HICS disenrollments in 2026, and what visibility does Astrana have into these declines?
A:Astrana expects approximately 10% Medicaid disenrollments and low tens of percentages for HICS disenrollments. Medicaid enrollment is monitored in real-time, with historical monthly losses of 0.5%-1%.
Q:How is the Prospect integration affecting member engagement metrics, and what are the expected outcomes?
A:The integration is improving member engagement metrics, such as annual wellness visits, through combined clinical and quality teams and technology platforms. While specific numbers are not yet available, strong engagement and quality score growth are expected.
Q:Is there any seasonality or M&A activity included in the 2026 guidance?
A:The 2026 guidance does not include any planned M&A activity. Seasonality is expected, with Q3 being a stronger quarter, consistent with prior years.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantifications for the impact of the 2027 MA advanced notice on Astrana's risk model and the exact growth rate for Medicare Advantage. Additionally, they did not provide detailed numbers for the annual wellness visit improvements at Prospect or the exact contributions of AI tools to G&A reductions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Astrana care
CMS
alignment
approach risk
authorization
care enablement
care model
completion rate
complexity
cost volatility
curve
cycle
discipline
economics
engagement
expansion market
exposure
intensity
legacy
market California
membership risk
model margin
outcome control
platform position
predictability risk
respect risk
result detail
review risk
risk model
risk progression
stability
strength care
structure
technology AI
technology leverage
track record
underwriting
visit completion
workflow
ASTH Transcript
Astrana Health, Inc. (ASTH) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call indicates strong financial performance with record-high adjusted EPS and optimistic guidance for 2026 and 2027. The integration of Prospect Health and strategic partnerships are progressing well, and AI tools are enhancing operational efficiency. Despite some concerns about Medicaid disenrollments and management's lack of specific quantifications, the overall sentiment is positive. The expanded partnerships and AI deployment are likely to boost short-term stock price, leading to a positive outlook.
Astrana Health, Inc. (ASTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Astrana Health, Inc. (ASTH) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call indicates positive sentiment with strong revenue guidance for 2025, optimistic medium-term EBITDA projections, and a strategic partnership with Intermountain Health. Despite a minor EBITDA reduction due to timing delays, the company's focus on deleveraging and synergy savings, along with stable cash flow and improving Medicaid trends, are favorable. The Q&A section did not reveal significant negative concerns, and the partnership and revenue growth are expected to positively impact the stock price.
Astrana Health, Inc. (ASTH) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents mixed signals. While there are positive aspects like market expansion, breakeven achievements, and optimistic guidance, there are significant concerns such as potential revenue headwinds from Medicaid changes and lack of clarity in management's responses. The company's conservative approach in its guidance and the impact of legislative changes in California also add uncertainty. These factors, combined with the absence of a market cap, suggest a neutral stock price movement in the short term.
ASTH Slides
ASTH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
